Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2009
07/30/2009WO2008149140A3 Tegaserod oxalate and polymorphic forms
07/30/2009WO2008149139A3 Tegaserod fumarate and polymorphic forms
07/30/2009WO2008147798A3 Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition
07/30/2009WO2008134265A3 Iminosugar for treatment of tumors
07/30/2009WO2008127975A3 Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
07/30/2009WO2008116032A8 Compositions and methods for inhibiting tumor cell growth
07/30/2009WO2008109352A8 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
07/30/2009WO2008103613A3 Hydroxylamine compounds and methods of their use
07/30/2009WO2008100449A4 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
07/30/2009WO2008098104A8 Inhibitors of akt activity
07/30/2009WO2008076810A9 Azabicyclic heterocycles as cannabinoid receptor modulators
07/30/2009WO2008073957A8 Compounds and methods for modulating the silencing of a polynucleotide of interest
07/30/2009WO2008071169A3 Method for the production of specific inhibitors of 11-beta-hydroxysteroid dehydrogenase, in particular type 1 with basic nor-oleanan or nor-ursan frameworks
07/30/2009WO2008052044A3 Use of derivatives of propofol for treating diseases associated with oxidative stress
07/30/2009WO2007146716A3 Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
07/30/2009WO2007112753A8 Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
07/30/2009US20090193534 Transforming oviduct tissue of birds with nucleotide sequences coding mammalian polypeptides; tissue engineering
07/30/2009US20090192306 Cephalosporin in Crystalline Form
07/30/2009US20090192230 Propofol-containing fat emulsion preparation
07/30/2009US20090192229 2-Aminoalcohols for the Treatment of Neurodegenerative Diseases
07/30/2009US20090192228 Controlled-Release Tolterodine Compositions and Methods
07/30/2009US20090192227 N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
07/30/2009US20090192226 Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation
07/30/2009US20090192225 Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use
07/30/2009US20090192224 Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
07/30/2009US20090192223 Gip secretion inhibitor
07/30/2009US20090192222 Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
07/30/2009US20090192221 Carbamate antibiotics
07/30/2009US20090192220 Treatment for solid tumors
07/30/2009US20090192218 Use of phthalide derivatives for the treatment and prevention of diabetes mellitus
07/30/2009US20090192217 Method and composition for treating acne using lignan compounds
07/30/2009US20090192216 Methods for the formulation and manufacture of artesunic acid for injection
07/30/2009US20090192215 Cytotoxin Compounds and Methods of Isolation
07/30/2009US20090192214 Drug delivery from rapid gelling polymer composition
07/30/2009US20090192213 Benzo[b]furane And Benzo[b]thiophene Derivatives
07/30/2009US20090192212 Dithiol Compounds, Derivatives, and Uses Therefor
07/30/2009US20090192211 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
07/30/2009US20090192210 Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
07/30/2009US20090192209 Extended treatment of tumors through vessel occlusion with light activated drugs
07/30/2009US20090192206 Mercaptoimidazoles as ccr2 receptor antagonists
07/30/2009US20090192205 Process for release of biologically active species
07/30/2009US20090192204 N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
07/30/2009US20090192203 Compounds and compositions as ppar modulators
07/30/2009US20090192202 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle; selective androgen receptor modulators; decrease excess sebum secretions; stimulants of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer
07/30/2009US20090192201 Composition and method for treating and preventing musculoskeletal and connective tissue disorders
07/30/2009US20090192200 Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
07/30/2009US20090192199 Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
07/30/2009US20090192198 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
07/30/2009US20090192197 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate
07/30/2009US20090192195 Compounds Having CRTH2 Antagonist Activity
07/30/2009US20090192194 Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them
07/30/2009US20090192193 Diagnostic agent and method for detection of cancer and a means for treatment of same
07/30/2009US20090192192 Inhibitors of biofilm formation of gram-positive and gram-negative bacteria
07/30/2009US20090192191 Substituted hydroxamic acid derivatives as tnf inhibitors
07/30/2009US20090192190 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR
07/30/2009US20090192189 Treatment of cancers expressing p95 erbb2
07/30/2009US20090192188 Tetrahydroisoquinoline derivatives
07/30/2009US20090192187 Dry powder formulation comprising an anticholinergic drug
07/30/2009US20090192186 Biaryl substituted azabicyclic alkane derivatives
07/30/2009US20090192185 Medical product
07/30/2009US20090192184 Crystalline Polymorphs of Topotecan Hydrochloride and Methods for the Preparation Thereof
07/30/2009US20090192183 Oxymorphone Controlled Release Formulations
07/30/2009US20090192182 Compound having acidic group which may be protected, and use thereof
07/30/2009US20090192181 Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
07/30/2009US20090192180 Alpha-7 Nicotinic Receptor Agonists and Statins In Combination
07/30/2009US20090192179 Chroman derivatives
07/30/2009US20090192178 mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS
07/30/2009US20090192177 2-ARYL pyrrologpyrimidines for A1 and A3 receptors
07/30/2009US20090192176 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
07/30/2009US20090192174 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action
07/30/2009US20090192173 Anti-tubercular drugs: compositions and methods
07/30/2009US20090192171 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
07/30/2009US20090192170 N-((S)-1-cyclopentyl-2-oxo-2-((3aS,6aR)-3-oxodihydro-2H-furo[3,2-b]pyrrol-4(5H,6H,6aH)-yl)ethyl)-4-(4-methylpiperazin-1-yl)benzamide; osteoporosis, Paget's disease, Chagas's, malaria, gingival diseases, hypercalcemia, metabolic bone disease, bone cancer and associated pain
07/30/2009US20090192169 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
07/30/2009US20090192168 Compounds, Compositions and Methods
07/30/2009US20090192166 Method for augmenting the effects of serotonin reuptake inhibitors
07/30/2009US20090192164 Treating agent of inflammatory bowel disease
07/30/2009US20090192163 Novel Compounds
07/30/2009US20090192162 Phenoxy Acetic Acids as PPAR Delta Activators
07/30/2009US20090192161 Amorphous and Crystalline Forms of Aprepitant and Processes for the Preparation Thereof
07/30/2009US20090192160 Compounds
07/30/2009US20090192159 Substituted gamma lactams as therapeutic agents
07/30/2009US20090192158 Methods for Treating or Preventing Neoplasias
07/30/2009US20090192157 Indole compounds and methods for treating visceral pain
07/30/2009US20090192156 Phthalazinone derivatives
07/30/2009US20090192155 Identification of Compounds Suitable for Treating Ad
07/30/2009US20090192154 Sultam derivatives
07/30/2009US20090192153 Novel adenine compound
07/30/2009US20090192152 Novel Antigiardial Agents and Methods of Use Thereof
07/30/2009US20090192151 Therapeutic amides and related compounds
07/30/2009US20090192150 protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants
07/30/2009US20090192149 Imidazo Compounds
07/30/2009US20090192148 Organic Compounds
07/30/2009US20090192147 [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
07/30/2009US20090192146 Substituted organosulfur compounds and methods of using thereof
07/30/2009US20090192145 Spiro-Imidazo Compounds
07/30/2009US20090192144 Imidazo Compounds
07/30/2009US20090192143 Substituted diazepan orexin receptor antagonists
07/30/2009US20090192142 Use of carbamazepine derivatives for the treatment of agitation in dementia patients
07/30/2009US20090192141 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
1 ... 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 ... 7860